Resources from the same session
5005 - Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study
Presenter: Suresh Ramalingam
Session: Proffered paper session - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
5121 - Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study
Presenter: Vassiliki Papadimitrakopoulou
Session: Proffered paper session - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
Proffered paper session - NSCLC, metastatic - Invited Discussant LBA50 and one LBA TBC
Presenter: Charles Rudin
Session: Proffered paper session - NSCLC, metastatic
Resources:
Slides
Webcast
Invited Discussant LBA 52
Presenter: James Chih-Hsin Yang
Session: Proffered paper session - NSCLC, metastatic
Resources:
Slides
Webcast
5153 - Phase 2 study of tepotinib + gefitinib (TEP+GEF) in MET-positive (MET+)/epidermal growth factor receptor (EGFR)-mutant (MT) non-small cell lung cancer (NSCLC)
Presenter: Yi-Long Wu
Session: Proffered paper session - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
2110 - Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC280) in patients (pts) with METΔex14 mutated advanced non-small cell lung cancer (NSCLC)
Presenter: Juergen Wolf
Session: Proffered paper session - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast